From Yahoo Finance: 2025-05-29 00:09:00

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) reports positive early results from Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer, showing a 59% PSA50 response rate and a 24% confirmed PSA90 response rate. Patients on therapy for nearly a year or more.

Safety data reveals majority of adverse events are mild or moderate, supporting long-term dosing suitability. Plans to advance two Phase 2 doses for each combination into further study, with a global Phase 3 trial starting in the first half of 2026. ORIC secures $125 million to fund trials through 2027.

Read more: ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials